San Mateo, Calif., and Cambridge, Mass., October 24, 2019 – Kronos Bio, Inc., a developer of first-in-class
therapies that modulate historically undruggable targets, announced today that it has expanded its senior
management team in newly created positions with the appointments of Christopher Lee, Ph.D. as Vice
President, Program Management, and Charles Lin, Ph.D., as Vice President, Biology.
Dr. Lee will play a critical role in establishing a Program Management function at Kronos across both its
San Mateo and Cambridge offices. He will begin working at the company on November 4, 2019, in the
San Mateo office. Dr. Lin will focus on the discovery of novel small molecules that modulate historically
undruggable oncology targets. He will also develop Kronos’ bioinformatics capability, which will allow the
company to fully leverage genomic and proteomic insights in the advancement of its discovery pipeline.
Dr. Lin will begin his role at the company on December 20, 2019, in the Cambridge office.
“Chris and Charles have highly relevant track records in biopharma and academia, respectively, and their
ability to help drive our pipeline strategy and platform will be invaluable as we grow,” said Norbert
Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. “Chris has nearly 20 years of
research and project management experience from discovery through Phase 3 development and
commercialization. Charles has been a rising star in academic medicine and has deep expertise in
epigenetics and oncogenic transcription, which is ideally matched to our research focus on novel
modulators or degraders of historically undruggable targets. His experience as a computational biologist
will be essential in our discovery efforts against a range of validated, historically challenging oncology
targets and in gleaning insights into underlying target biology.”
“I look forward to joining Kronos at this critical time in the company’s development as it continues to
grow and mature its internal discovery pipeline,” said Dr. Lee. “Having spent my entire career involved in
biopharmaceutical research and program management, I am excited to bring to Kronos my experience in
drug research and clinical development strategy, team dynamics, risk mitigation and timeline
“After my time in academia, I decided to enter the biopharmaceutical industry because I wanted to
make a more tangible impact on patient treatment. I am joining Kronos because of its impressive
management team and Small Molecule Microarray platform, which has identified bioactive molecules
against challenging oncology targets,” said Dr. Lin. “I look forward to leveraging my experience in
altered gene control to help Kronos advance its promising pipeline of novel targets to address some of
the most challenging diseases patients face today.”
Dr. Lee is joining Kronos from Gilead Sciences where he spent 19 years in roles of increasing
responsibility. Most recently, he served as Senior Director, Research Portfolio Management, where he
established a new Project Management department supporting research teams for projects in preclinical
and clinical development across the company’s portfolio, including in oncology. Prior to becoming a
project manager, Dr. Lee was a research scientist in the Medicinal Chemistry department. He earned a
B.S. in chemistry from the University of California, Berkeley, a Ph.D. in organic chemistry from the
University of California, Los Angeles, and an M.B.A. from Golden Gate University.
Dr. Lin is joining Kronos from Baylor College of Medicine, where he served as an Assistant Professor in the
Department of Molecular and Human Genetics, a Pew-Stewart Scholar for Cancer Research, a CPRIT
Scholar in Cancer Research, and was a scientific founder and Co-Director of the Therapeutic Innovation
Center, an academic research center focused on accelerating therapeutic discovery against diseases of
altered gene control. Dr. Lin was recruited to Baylor of College of medicine by the Cancer Prevention and
Research Institute of Texas. In his interdisciplinary laboratory, Dr. Lin has investigated and targeted
transcriptional deregulation in cancer. He received a B.S. in biology and physics from Duke University and
a Ph.D. in computational and systems biology from the Massachusetts Institute of Technology. He
completed a post-doctoral fellowship in the Department of Medical Oncology and Chemical Biology
Program at the Dana-Farber Cancer Institute where he focused on targeting deregulation of transcription
and chromatin regulators in cancer.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.
# # #